StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 10, 2026, 04:29 PM

Nkarta Q2 Net Loss Widens to $40.37M; Operating Expenses Up

AI Summary

Nkarta, Inc. reported a significant increase in net loss for the second quarter of 2026, reaching $40.37 million, compared to $22.98 million in the prior year. This was primarily driven by a substantial rise in research and development and general and administrative expenses. The company also recorded impairment charges totaling $8.05 million related to property and equipment and right-of-use assets. Despite current liquidity, management anticipates needing additional capital to fund ongoing research and development activities.

Key Highlights

  • Net loss for Q2 2026 widened to $40.37 million from $22.98 million in Q2 2025.
  • Net loss for H1 2026 increased to $68.20 million from $54.96 million in H1 2025.
  • Research and development expenses rose to $29.05 million in Q2 2026, up from $20.78 million.
  • General and administrative expenses increased to $14.08 million in Q2 2026 from $6.41 million.
  • Recorded $5.67 million impairment for property and equipment in H1 2026.
  • Recorded $2.38 million impairment for right-of-use assets in H1 2026.
  • Cash, cash equivalents, restricted cash, and investments totaled $243.2 million as of June 30, 2026.
  • Accumulated deficit reached $716.5 million as of June 30, 2026.